Next‐generation ALK inhibitor vs crizotinib
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with crizotinib (high certainty).
1 finding from 1 review
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes onlyHR 0.25 [0.19, 0.34]5 studies · 406 participantsHigh